ZTS vs PAHC

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 18. 5x trailing P/E (15. 8x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 18. 5x versus Phibro Animal Health Corporation at 49. 3x. On forward P/E, Zoetis Inc. is actually cheaper at 15. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 1. 32x versus Phibro Animal Health Corporation's 2. 59x — a reasonable growth-adjusted valuation.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +136.

4%, compared to -28. 8% for Zoetis Inc. (ZTS). Over 10 years, the gap is even starker: PAHC returned +207. 3% versus ZTS's +158. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zoetis Inc.

(ZTS) is the lower-risk stock at 0. 90β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 52% more volatile than ZTS relative to the S&P 500. On balance sheet safety, Phibro Animal Health Corporation (PAHC) carries a lower debt/equity ratio of 3% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 10. 1% for Zoetis Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 1. 32x versus Phibro Animal Health Corporation's 2. 59x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zoetis Inc. (ZTS) trades at 15. 8x forward P/E versus 19. 3x for Phibro Animal Health Corporation — 3. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 28. 6% to $143. 00.

All stocks in this comparison pay dividends.

Zoetis Inc. (ZTS) offers the highest yield at 1. 8%, versus 0. 8% for Phibro Animal Health Corporation (PAHC).

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 1. 8% yield, +158. 5% 10Y return). Both have compounded well over 10 years (ZTS: +158. 5%, PAHC: +207. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZTS is a mid-cap quality compounder stock; PAHC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.